China has developed six domestically approved surgical robot platforms to challenge da Vinci's dominance. Here is what the clinical evidence shows — and why cost matters for international patients.
For over a decade, robotic surgery in China primarily meant the da Vinci Surgical System (Intuitive Surgical, US). China's hospitals operated over 300 da Vinci systems by 2020, making it one of the largest markets outside the United States. At USD 1.5–2 million per system plus high consumable costs, da Vinci created significant access inequality between elite urban hospitals and provincial centers.
China's Surgical Robot Market: From Import Dependency to Domestic Production
For over a decade, robotic surgery in China primarily meant the da Vinci Surgical System (Intuitive Surgical, US). China's hospitals operated over 300 da Vinci systems by 2020, making it one of the largest markets outside the United States. At USD 1.5–2 million per system plus high consumable costs, da Vinci created significant access inequality between elite urban hospitals and provincial centers.
China's coordinated strategy to develop domestic surgical robot platforms has now produced commercially deployed products with NMPA approval. By early 2025, six domestically developed robotic surgery systems had received NMPA clearance for laparoscopic, orthopedic, or neurosurgical indications.
The Domestic Platforms
- MicroPort MedBot — Toumai (Shanghai): China's first domestically developed laparoscopic surgical robot to receive NMPA approval (2022). Designed for urologic surgery including radical prostatectomy and partial nephrectomy.
- Tinavi Medical — Tianji Robot (Beijing): NMPA-approved orthopedic surgical robot for spine and joint procedures. One of the most widely installed Chinese surgical robots by hospital count, deployed in over 500 hospitals by 2024.
- Remebot (Beijing): Stereotactic neurosurgical robot, installed at over 100 neurosurgical centers across China, with documented use in deep brain stimulation and stereotactic biopsy procedures.
Toumai Clinical Evidence
MicroPort's Toumai system is the most publicly documented Chinese laparoscopic robot with published comparative clinical data. Studies comparing Toumai to conventional laparoscopy and to da Vinci for radical prostatectomy have been presented at Chinese urological conferences and published in Chinese and international journals. The published data demonstrates that Toumai achieves surgical outcomes — including positive surgical margin rates and continence recovery — comparable to da Vinci in the hands of experienced surgeons, at significantly lower per-procedure cost due to lower consumable pricing.
AI Integration in China's Surgical Robots
China's domestic surgical robot platforms are actively differentiating on AI integration:
- Intraoperative tissue recognition: AI systems identifying critical anatomical structures (ureters, blood vessels, nerves) in real-time to reduce inadvertent injury risk during laparoscopic procedures
- Surgical workflow recognition: AI phase recognition to provide context-appropriate guidance and risk alerts during standardized procedure steps
- Autonomous task research: Research platforms at Zhejiang University and Shanghai Jiao Tong University have demonstrated AI-assisted suturing in laboratory settings, with clinical applications under development
- Haptic feedback: Multiple domestic platforms are incorporating force sensing with AI interpretation — an area where da Vinci's standard platform has lacked native haptic feedback
Neurosurgery: Remebot's Track Record
Stereotactic neurosurgery — placing electrodes or biopsy needles at precise intracranial targets — was one of China's earliest robotic surgery applications. Remebot's system has performed over 10,000 documented procedures across 100+ neurosurgical centers for deep brain stimulation, stereotactic biopsy, and functional neurosurgery. Published analyses demonstrate targeting accuracy within accepted clinical tolerance for DBS electrode placement, with AI-assisted trajectory planning reducing setup time compared to conventional frame-based approaches.
What This Means for International Surgical Patients
For patients considering robotic surgery in China, the 2025 landscape offers genuine choice. Da Vinci systems are available at major Class 3A hospitals. For procedures where domestic robots have published non-inferiority data — prostatectomy, joint arthroplasty, stereotactic neurosurgery — patients can access robotic procedures at lower overall cost than comparable Western centers. Combined with China's lower facility fees and surgical team costs, robotic surgery in China offers a compelling cost-quality combination for international patients.
Sources: MicroPort MedBot NMPA approval documentation 2022; Tinavi Medical deployment data 2024; Remebot clinical program documentation; European Urology (robotic prostatectomy comparative literature); Grand View Research China surgical robotics market 2024.